Have a Claim?

Click here for a confidential contact or call:

1-212-350-2764

December 16, 2015

Posted  January 25, 2016

Qualitest Pharmaceuticals, the company’s corporate shell, Vintage Pharmaceuticals, its parent Endo Pharmaceuticals, and seven of their affiliates, agreed to pay $39 million to 48 states and the federal government to settle charges they violated federal and state False Claims Acts by selling understrength chewable fluoride tablets.  As part of the settlement, Qualitest admitted the drug labeling for its chewable fluoride tablets represented fluoride amounts in line with guidelines of the American Dental Association and the American Academy of Pediatrics when in reality it used less than half of these represented amounts.  The allegations were first raised in a whistleblower lawsuit brought Dr. Stephan Porter under the qui tam provisions of the False Claims Act.  He will receive a whistleblower award of roughly $4.71 million from the proceeds of the government’s recovery.  Whistleblower Insider, NY, NH

Tagged in: Defective Products, Drug Switching, FCA Federal, FCA State, Pharma Fraud, Whistleblower Case, Whistleblower Rewards,

Newsletter

Subscribe to receive email updates from the Constantine Cannon blogs

Sign up for: